Feline Calicivirus Virulent Systemic Disease: Clinical Epidemiology, Analysis of Viral Isolates and In Vitro Efficacy of Novel Antivirals in Australian Outbreaks
Bordicchia, Matteo, Fumian, Tulio Machado, Van Brussel, Kate, Russo, Alice G., Carrai, Maura, Le, Shi-Jia, Pesavento, Patricia A., Holmes, Edward C., Martella, Vito, White, Peter, Beatty, Julia A., Shi, Mang, and Barrs, Vanessa R. (2021) Feline Calicivirus Virulent Systemic Disease: Clinical Epidemiology, Analysis of Viral Isolates and In Vitro Efficacy of Novel Antivirals in Australian Outbreaks. Viruses, 13 (10). 2040.
|
PDF (Published Version)
- Published Version
Available under License Creative Commons Attribution. Download (4MB) | Preview |
Abstract
Feline calicivirus (FCV) causes upper respiratory tract disease (URTD) and sporadic outbreaks of virulent systemic disease (FCV-VSD). The basis for the increased pathogenicity of FCV-VSD viruses is incompletely understood, and antivirals for FCV-VSD have yet to be developed. We investigated the clinicoepidemiology and viral features of three FCV-VSD outbreaks in Australia and evaluated the in vitro efficacy of nitazoxanide (NTZ), 2′-C-methylcytidine (2CMC) and NITD-008 against FCV-VSD viruses. Overall mortality among 23 cases of FCV-VSD was 39%. Metagenomic sequencing identified five genetically distinct FCV lineages within the three outbreaks, all seemingly evolving in situ in Australia. Notably, no mutations that clearly distinguished FCV-URTD from FCV-VSD phenotypes were identified. One FCV-URTD strain likely originated from a recombination event. Analysis of seven amino-acid residues from the hypervariable E region of the capsid in the cultured viruses did not support the contention that properties of these residues can reliably differentiate between the two pathotypes. On plaque reduction assays, dose–response inhibition of FCV-VSD was obtained with all antivirals at low micromolar concentrations; NTZ EC50, 0.4–0.6 µM, TI = 21; 2CMC EC50, 2.7–5.3 µM, TI > 18; NITD-008, 0.5 to 0.9 µM, TI > 111. Investigation of these antivirals for the treatment of FCV-VSD is warranted.
Item ID: | 82791 |
---|---|
Item Type: | Article (Research - C1) |
ISSN: | 1999-4915 |
Copyright Information: | © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
Date Deposited: | 21 May 2024 03:15 |
FoR Codes: | 30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES > 3009 Veterinary sciences > 300914 Veterinary virology @ 50% 31 BIOLOGICAL SCIENCES > 3107 Microbiology > 310706 Virology @ 50% |
SEO Codes: | 20 HEALTH > 2099 Other health > 209999 Other health not elsewhere classified @ 100% |
Downloads: |
Total: 13 Last 12 Months: 6 |
More Statistics |